Ignite Creation Date:
2024-05-06 @ 2:58 AM
Last Modification Date:
2024-10-26 @ 11:26 AM
Study NCT ID:
NCT02177435
Status:
COMPLETED
Last Update Posted:
2014-07-08
First Post:
2014-06-26
Brief Title:
Telmisartan With or Without Hydrochlorothiazide in Patients With Mild-to-moderate Hypertension
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
An Eight Week Randomized Double-Blind Study Comparing a Fixed Dose Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 125 mg to Telmisartan 80 mg in Patients Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg
Status:
COMPLETED
Status Verified Date:
2014-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Study to demonstrate that a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide HCTZ 125 mg FDC 80125 is superior to telmisartan 80 mg Telm 80 alone in patients who failed to respond adequately to Telm 80 monotherapy in lowering seated trough diastolic blood pressure DBP after eight weeks of treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None